FDMT Stock Forecast & Price Target

4D Molecular Therapeutics is supported by a compelling wet AMD thesis centered on 4D-150, whose single-dose design aims to deliver sustained aflibercept expression, reduce VEGF signaling, and meaningfully lessen the chronic injection burden that still limits current anti-VEGF care. Phase 2b PRISM data showed durable efficacy and safety, including 78% overall treatment-burden reduction over 2 years, 87% reduction in recently diagnosed patients, and no new inflammation after the 20-week steroid taper, while the Phase 3 4FRONT-1 and 4FRONT-2 programs are already fully enrolled and designed for non-inferiority on Week 52 BCVA. The outlook is further strengthened by the potential for a clinically seamless, in-office intravitreal workflow, strong physician interest in a backbone therapy, and a credible path to over $1B in peak 150 revenue by 2033, despite development, regulatory, and commercialization risks.

4D Molecular Therapeutics is viewed negatively because its core 4FRONT studies appear structurally biased in favor of 4D-150, making efficacy readouts harder to trust against real-world wet AMD care where treat-and-extend and PRN Eylea use are highly heterogeneous. The company also faces a crowded gene therapy landscape, while its programs remain early and still require more capital, raising dilution and execution risk before any durable commercial upside can be proven. In addition, the elderly patient mix may complicate Medicare coverage for a therapy framed around a roughly 5 year benefit horizon, further weakening the path to adoption.